Voloridge Investment Management
SRNE

Voloridge Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Voloridge Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-169,029
Closed -$786K – 1804
2021
Q4 		$786K Buy
+169,029
New +$1.05M ﹤0.01% 1328

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Voloridge Investment Management's SRNE Position: Q1 2022 in Review

Voloridge Investment Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 169,029 shares — an estimated $786K sold.

Voloridge Investment Management first reported a position in SRNE in Q4 2021 and held it in 1 quarter. The position peaked at $786K in Q4 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

  • Voloridge Investment Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 169,029 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $786K.
  • Voloridge Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
  • Voloridge Investment Management's Sorrento Therapeutics, Inc. position peaked at $786K in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Voloridge Investment Management's 13F filing for Q1 2022, filed 16 May 2022.